mTOR-inhibitors and post-transplant diabetes mellitus: a link still debated in kidney transplantation

mTOR-inhibitors and post-transplant diabetes mellitus: a link still debated in kidney transplantation

The mammalian target of rapamycin inhibitors (mTOR-Is, Sirolimus, and Everolimus) are immunosuppressive drugs widely employed in kidney transplantation. Their main mechanism of action includes the inhibition of a serine/threonine kinase with a pivotal role in cellular metabolism and in various eukar...

Full description

Bibliographic Details
Main Authors:	Simona Granata, Silvia Mercuri, Dario Troise, Loreto Gesualdo, Giovanni Stallone, Gianluigi Zaza
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Medicine
Subjects:	post-transplant diabetes mellitus kidney transplantation immunosuppressive drugs allograft co-morbidities mTOR-inhibitor
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2023.1168967/full

Similar Items

Medical Aspects of mTOR Inhibition in Kidney Transplantation
by: Elena Cuadrado-Payán, et al.
Published: (2022-07-01)

The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma
by: Letizia Todeschini, et al.
Published: (2023-06-01)

mTOR-Inhibition and COVID-19 in Kidney Transplant Recipients: Focus on Pulmonary Fibrosis
by: Simona Granata, et al.
Published: (2021-08-01)

Polymorphisms in mTOR and Calcineurin Signaling Pathways Are Associated With Long-Term Clinical Outcomes in Kidney Transplant Recipients
by: Antony Brayan Campos-Salazar, et al.
Published: (2018-11-01)

Cancer and mTOR inhibitors in kidney transplantation recipients
by: Chih-Chin Kao, et al.
Published: (2018-11-01)

mTOR Inhibitors Induce Erythropoietin Resistance in Renal Transplant Recipients
by: Reece Jefferies, et al.
Published: (2022-02-01)

Liver Transplantation: What Every Gastroenterologist Should Know about It
by: Reza F. Saidi
Published: (2018-04-01)

mTOR Inhibitor Use Is Associated With a Favorable Outcome of COVID-19 in Patients of Kidney Transplant: Results of a Retrospective Study
by: Biagio Pinchera, et al.
Published: (2022-06-01)

Skin cancer in solid organ transplant recipients: still an open problem
by: Simona Granata, et al.
Published: (2023-04-01)

Sirolimus-Based Immunosuppression Is Associated with Decreased Incidence of Post-Transplant Lymphoproliferative Disorder after Heart Transplantation: A Double-Center Study
by: Rabea Asleh, et al.
Published: (2022-01-01)

Conversion to mTOR-Inhibitors Plus IV Immunoglobulins in Kidney-Transplant Recipients with BKV Infection: A Retrospective Comparative Study
by: Carla Vela, et al.
Published: (2022-12-01)

Selective Effects of mTOR Inhibitor Sirolimus on Naïve and CMV-Specific T Cells Extending Its Applicable Range Beyond Immunosuppression
by: Szilvia Bak, et al.
Published: (2018-12-01)

The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients
by: Susan L. Murray, et al.
Published: (2020-01-01)

Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation
by: Rabea Asleh, et al.
Published: (2022-02-01)

Clinical and preclinical tolerance protocols for vascularized composite allograft transplantation
by: Jerry Huanda Yang, et al.
Published: (2021-11-01)

Allograft nephrectomy vs. no nephrectomy for failed renal transplants
by: Michelle McDonald, et al.
Published: (2023-07-01)

Mammalian target of rapamycin inhibitors: A paradigm shift in current immunosuppression protocols
by: Indranil Ghosh, et al.
Published: (2016-01-01)

Real-Life Experience of mTOR Inhibitors in Liver Transplant Recipients in a Region Where Living Donation Is Predominant
by: Pil Soo Sung, et al.
Published: (2021-07-01)

Expression of mTOR in normal and pathological conditions
by: A Marques-Ramos, et al.
Published: (2023-07-01)

Lung Transplantation and the Era of the Sensitized Patient
by: Katherine A. Young, et al.
Published: (2021-05-01)

Myeloid-Derived Suppressor Cells in Kidney Transplant Recipients and the Effect of Maintenance Immunotherapy
by: María Iglesias-Escudero, et al.
Published: (2020-04-01)

Metabolic Disruption Induced by mTOR Signaling Pathway Inhibition in Regulatory T-Cell Expansion for Clinical Application
by: Roberto Gedaly, et al.
Published: (2023-08-01)

Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term Outcomes
by: J Kumar, et al.
Published: (2017-04-01)

Transplantation Tolerance through Hematopoietic Chimerism: Progress and Challenges for Clinical Translation
by: Benedikt Mahr, et al.
Published: (2017-12-01)

Immunosuppression in transplant of vascularized composite allografts
by: Andreea GROSU-BULARDA, et al.
Published: (2016-06-01)

Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities
by: Julio Pascual, et al.
Published: (2017-05-01)

Effects of Antirejection Drugs on Innate Immune Cells After Kidney Transplantation
by: Gianluigi Zaza, et al.
Published: (2019-12-01)

Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature
by: Giuseppe Tarantino, et al.
Published: (2016-10-01)

Overview of Research into mTOR Inhibitors
by: Beibei Mao, et al.
Published: (2022-08-01)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
by: Zhilin Zou, et al.
Published: (2020-03-01)

Incidence of Cytomegalovirus disease in kidney transplant recipients receiving Everolimus and reduced Tacrolimus doses: A cohort retrospective analysis
by: Juliana Bastos, et al.
Published: (2021-10-01)

Continuation of immunosuppression vs. immunosuppression weaning in potential repeat kidney transplant candidates: a care management perspective
by: Michelle J. Hickey, et al.
Published: (2023-06-01)

Characteristics, Predictors, and Outcomes of Early mTOR Inhibitor Use After Heart Transplantation: Insights From the UNOS Database
by: Polydoros N. Kampaktsis, et al.
Published: (2022-09-01)

Respiratory distress of unknown etiology in a transplant recipient: think toxoplasmosis!
by: Ameer Hamza, et al.
Published: (2017-12-01)

Long-Term Redistribution of Peripheral Lymphocyte Subpopulations after Switching from Calcineurin to mTOR Inhibitors in Kidney Transplant Recipients
by: Laura Llinàs-Mallol, et al.
Published: (2020-04-01)

Predictors of allograft survival and patient survival in living donor renal transplant recipients
by: Pinaki Mukhopadhyay, et al.
Published: (2017-01-01)

Mechanistic Target of Rapamycin (mTOR) in the Cancer Setting
by: James T. Murray, et al.
Published: (2018-05-01)

Clinical Implications of mTOR Expression in Papillary Thyroid Cancer—A Systematic Review
by: Aleksandra Derwich, et al.
Published: (2023-03-01)

Inflammasome pathway in kidney transplantation
by: Simona Granata, et al.
Published: (2023-11-01)

Immunologic barriers in liver transplantation: a single-cell analysis of the role of mesenchymal stem cells
by: Haitao Li, et al.
Published: (2023-12-01)